Brief: Apellis Pharmaceuticals Says To Submit Supplemental NDA To FDA In Early 2025

Apellis Pharmaceuticals

26/10/2024 19:01

Oct 26 (Reuters) - Apellis Pharmaceuticals Inc  APLS.O :
    * PIVOTAL VALIANT RESULTS PRESENTED AT KIDNEY WEEK HIGHLIGHT
STRENGTH OF PEGCETACOPLAN TREATMENT EFFECT IN PATIENTS WITH C3G
/ PRIMARY IC-MPGN
    * APELLIS PHARMACEUTICALS INC - ALL SECONDARY ENDPOINTS
FAVORED
PEGCETACOPLAN TREATMENT
    * APELLIS PHARMACEUTICALS INC - TO SUBMIT SUPPLEMENTAL NDA
TO FDA
IN EARLY 2025

Source text:  ID:nGNX7RnZk4 
Further company coverage:  APLS.O 

 ((Reuters.Briefs@thomsonreuters.com;;))